multiple myeloma
Overcoming real-world challenges to maximise the benefit of treatment for patients with multiple myeloma
October 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Takeda, multiple myeloma
Dr Antonio Palumbo, Distinguished Research Fellow Oncology, Takeda Pharmaceuticals addresses hwo far we’ve come in treating multiple myeloma, and how …
Rabbit virus proves effective in treatment of multiple myeloma
February 22, 2017Research and Development multiple myeloma
A team of researchers at the Medical University of South Carolina (MUSC) utilising the myxoma virus (MYXV) to treat multiple …
Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU
January 27, 2017Sales and Marketing Celgene, Revlimid, multiple myeloma
Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …
Takeda gains marketing authorisation for multiple myeloma pill
November 28, 2016Sales and Marketing Takeda, multiple myeloma
Takeda Pharmaceutical has announced that they have received conditional marketing authorisation for Ninlaro (ixazomib) for treatment of adult patients with …
J&J and Genmab’s drug races to second line treatment approval
November 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma
Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Darzalex receives breakthrough designation in multiple myeloma from FDA
July 26, 2016Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
June 10, 2016Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma
Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma. The company said …
Amgen showcases positive Phase III multiple myeloma drug at ASCO
June 7, 2016Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma
Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
June 6, 2016Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
Genmab receives milestone payment for first Darzalex sale in Europe
May 31, 2016Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales
Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …
Multiple myeloma treatment from BMS and AbbVie scores EU approval
May 12, 2016Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma
Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
Two CHMP nods for Janssen
April 4, 2016Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma
The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …
Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours
March 22, 2016Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour
Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
Amgen’s Kyprolis now available to UK multiple myeloma patients
February 12, 2016Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma
Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
Coriolis Pharma appoints Teun van der Heide as CEO
